S7 E9: Best DOAC for VTE; Muscle loss with GLP1s; CDSSs - why don't we use them?
NO
PHARMACEUTICAL INFLUENCE
17th April 2026
If you are having difficulties listening to this Podcast, try to play this episode in Spotify
Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we have three new pieces of research that affect us in general practice.
First: What interim anti-coagulation would you give your patient with suspected VTE? One common option has 5 times the rate of major bleeding.
Second: How much muscle mass do people lose with weight loss on GLP1s? Is this different from lifestyle-based interventions, and is there anything patients can do about it?
Third: Why don't we use clinical decision support tools for cancer? This research looks at the barriers and then I over-share my own thoughts on the subject...
References
NEJM Apixaban or rivaroxaban bleeding risk with acute VTE
Diabetes, Obesity & Metabolism Lean mass loss with incretin therapies vs lifestyle interventions
Join us at one of our upcoming courses or live webinars
